Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.58 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3864816 | 0.98 | HTR2C (0.59) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL12577717 | 0.84 | HTR2C (0.58) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL1633310 | 0.79 | KMO (0.71) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL30004901 | 0.77 | PARP1 (0.55) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL1668686 | 0.77 | HTR2C (0.54) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| Hydrochloric Acid SCHEMBL6709116 | 0.77 | KMO (0.69) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL233530 | 0.77 | HTR2C (0.57) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL30488777 | 0.77 | HTR2C (0.57) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL30945941 | 0.77 | HTR2C (0.54) | HTR2CSLC18A3SIGMAR1QDPRKMO | |
| SCHEMBL31706124 | 0.77 | HTR2C (0.57) | HTR2CSLC18A3SIGMAR1QDPRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| WO-2007133362-A1 | MODIFIED MEMBRANE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | HTR2C 442/4885SLC18A3 2079/4885SIGMAR1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.